Greenwich LifeSciences (GLSI) Competitors $10.84 -0.38 (-3.39%) Closing price 04:00 PM EasternExtended Trading$10.82 -0.02 (-0.14%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. ZVRA, TYRA, TSHA, OPT, BCYC, KURA, SEPN, ABVX, MAZE, and PRMEShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Its Competitors Zevra Therapeutics Tyra Biosciences Taysha Gene Therapies Opthea Bicycle Therapeutics Kura Oncology Septerna Abivax Maze Therapeutics Prime Medicine Greenwich LifeSciences (NASDAQ:GLSI) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability. Is GLSI or ZVRA more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -226.78%. Zevra Therapeutics' return on equity of -201.05% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -450.87% -333.18% Zevra Therapeutics -226.78%-201.05%-53.55% Which has better valuation & earnings, GLSI or ZVRA? Greenwich LifeSciences has higher earnings, but lower revenue than Zevra Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$15.79M-$1.26-8.60Zevra Therapeutics$23.61M29.02-$105.51M-$1.90-6.59 Which has more risk and volatility, GLSI or ZVRA? Greenwich LifeSciences has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Do analysts prefer GLSI or ZVRA? Greenwich LifeSciences currently has a consensus target price of $39.00, suggesting a potential upside of 259.78%. Zevra Therapeutics has a consensus target price of $23.71, suggesting a potential upside of 89.26%. Given Greenwich LifeSciences' higher probable upside, equities research analysts plainly believe Greenwich LifeSciences is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do insiders and institutionals have more ownership in GLSI or ZVRA? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor GLSI or ZVRA? In the previous week, Zevra Therapeutics had 11 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 12 mentions for Zevra Therapeutics and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.94 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Overall Sentiment Greenwich LifeSciences Very Positive Zevra Therapeutics Positive SummaryZevra Therapeutics beats Greenwich LifeSciences on 9 of the 15 factors compared between the two stocks. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.99M$2.92B$5.52B$9.07BDividend YieldN/A2.43%5.25%4.02%P/E RatioN/A20.7127.7220.26Price / SalesN/A182.01366.7878.98Price / CashN/A42.7337.4258.29Price / Book57.057.638.045.49Net Income-$15.79M-$55.05M$3.18B$250.27M7 Day Performance8.02%8.54%3.72%4.78%1 Month Performance12.56%5.38%3.72%7.20%1 Year Performance-31.31%2.35%29.92%17.27% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences2.2703 of 5 stars$10.84-3.4%$39.00+259.8%-28.9%$149.99MN/A0.003ZVRAZevra Therapeutics3.1917 of 5 stars$11.27+15.7%$23.14+105.3%+113.9%$532.58M$23.61M-5.9320News CoverageAnalyst ForecastHigh Trading VolumeTYRATyra Biosciences3.1725 of 5 stars$9.61-3.9%$30.83+220.8%-43.5%$530.90MN/A-5.9020TSHATaysha Gene Therapies4.0722 of 5 stars$2.34-4.5%$8.20+250.4%+12.8%$525.92M$8.33M-6.88180News CoverageAnalyst ForecastOPTOpthea0.3274 of 5 stars$3.41+7.2%$1.33-60.9%+72.6%$524.84M$120K0.008Gap UpBCYCBicycle Therapeutics3.7493 of 5 stars$7.17-3.5%$25.00+248.7%-61.5%$514.56M$35.28M-2.28240News CoverageKURAKura Oncology4.5084 of 5 stars$5.68-3.1%$24.50+331.3%-68.7%$507.33M$53.88M-2.70130Positive NewsSEPNSepterna1.4599 of 5 stars$10.85-4.6%$26.75+146.5%N/A$506.63M$1.08M0.00N/AABVXAbivax2.5704 of 5 stars$7.95-0.1%$31.00+289.9%-37.1%$505.10MN/A0.0061Positive NewsHigh Trading VolumeMAZEMaze TherapeuticsN/A$12.12+5.4%$25.67+111.8%N/A$503.67M$167.50M0.00121News CoverageAnalyst ForecastAnalyst RevisionPRMEPrime Medicine4.0423 of 5 stars$3.80+22.2%$10.08+165.4%-15.5%$498.92M$3.85M-1.85234Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ZVRA Competitors TYRA Competitors TSHA Competitors OPT Competitors BCYC Competitors KURA Competitors SEPN Competitors ABVX Competitors MAZE Competitors PRME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
